Orexo announces prospering completion of OX219 first pharmacokinetic trial for opioid dependenceOrexo AB announces self-made completion of the first pharmacokinetic trial in the OX219 project. In the relative bioavailability study, the OX219 buprenorphine/naloxone sublingual tablet formulation manifested favourable profiles gone to the comparator Suboxone®, which is the market entailing product for treatment of opioid dependence.Read [...]

Continue reading " Orexo announces successful completion of OX219 initial pharmacokinetic trial for opioid dependence "

The logo of DreamStream, LLC Beverly Hills, Calif. (PRWEB) July 5, 2008 In order to clarify an earlier press release, DreamStream issued a statement explaining the Motion Picture Association of America’s involvement in the presentation of DreamStream’s media streaming technology to the major motion picture studios. “DreamStream used unfortunate wording [...]

Continue reading " The MPAA Offers Initial Assessment – Not Endorsement – of DreamStream’s Technology "

Chicago, IL (PRWEB) December 1, 2006 Resonate Capital Management, LLC has acquired 50,000 common shares of an early stage aids vaccine manufacturer GeoVax Labs, Inc of Atlanta. The firm accumulated the common shares at open market pricing over the last seven trading days. Tony Wissel, A managing member of Resonate Capital believes that [...]

Continue reading " Resonate Capital Management Acquires an Initial 50,000 Shares of GeoVax Labs, Inc "